<?xml version="1.0" encoding="UTF-8"?>
<ref id="B86-ijms-22-00962">
 <label>86.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>David-Silva</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Esteves</surname>
    <given-names>J.V.</given-names>
   </name>
   <name>
    <surname>Morais</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Freitas</surname>
    <given-names>H.S.</given-names>
   </name>
   <name>
    <surname>Zorn</surname>
    <given-names>T.M.</given-names>
   </name>
   <name>
    <surname>Correa-Giannella</surname>
    <given-names>M.L.</given-names>
   </name>
   <name>
    <surname>Machado</surname>
    <given-names>U.F.</given-names>
   </name>
  </person-group>
  <article-title>Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non-alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice</article-title>
  <source>Diabetes Metab. Syndr. Obes. Targets Ther.</source>
  <year>2020</year>
  <volume>13</volume>
  <fpage>739</fpage>
  <lpage>751</lpage>
  <pub-id pub-id-type="doi">10.2147/DMSO.S242282</pub-id>
 </element-citation>
</ref>
